Which is better, tesamorelin or ipamorelin?
Tesamorelin has large randomized trials with a body composition endpoint, an FDA approval, and a lawful prescription path as Egrifta WR (as a biologic it cannot be compounded). Ipamorelin is also graded human RCT, but its one randomized trial tested intravenous dosing after bowel surgery and found no benefit, and no randomized trial has tested it for body composition. It was placed on the 503A Category 2 list in 2023 and is now a withdrawn 503A nomination. Tesamorelin's off label use for fat loss in people without HIV is still untested. [1] [3] [4] [6] [8] [13] [14]
How do tesamorelin and ipamorelin compare?
| Dimension | TesamorelinFavored | Ipamorelin |
|---|---|---|
| Mechanism [4] [5] [6] | Stabilized 44 amino acid GHRH analog acting on the pituitary GHRH receptor; feedback loops remain intact. | Pentapeptide ghrelin receptor (GHS-R1a) agonist; GH release through a separate pathway, also stimulates gut motility. |
| Evidence grade [1] [2] [3] [4] | Human RCT: pooled phase 3 trials (806 adults with HIV) and a 61 person liver fat RCT. | Human RCT: the one randomized trial (117 adults) tested intravenous ipamorelin for postoperative ileus and found no benefit. No randomized trial for GH related uses. |
| Key human results [1] [2] [3] | Visceral fat minus 24 versus plus 2 cm2 at 26 weeks (treatment effect minus 15.4%); liver fat fraction down an absolute 4.1% in HIV associated fatty liver. | Time to first tolerated meal 25.3 versus 32.6 hours on placebo (p = 0.15); no significant difference on any efficacy endpoint. |
| FDA status [3] [10] | FDA approved as Egrifta (2010), Egrifta SV (2019), and Egrifta WR (2025) to reduce excess abdominal fat in adults with HIV associated lipodystrophy. | Never approved anywhere; development stopped after the ileus trial. |
| Compounding status [7] [8] | Biologic since March 2020 (BLA 022505), so it is not eligible for 503A or 503B compounding; Egrifta WR by prescription is the only lawful product. | 503A Category 2 in September 2023, 503A nominations withdrawn in 2024; ipamorelin acetate remains in 503B Category 2. No federal basis for compounding. |
| Dosing [3] [10] [11] | FDA label: Egrifta WR 1.28 mg or Egrifta SV 1.4 mg injected under the skin of the abdomen once daily (the formulations are not substitutable); the phase 3 trials used 2 mg daily of the original Egrifta. Effect fades after stopping. | Not established for GH use; the human trial used 0.03 mg/kg intravenously twice daily for up to 7 days. |
| Side effects [3] [6] [8] | Arthralgia (about 13%), injection site reactions, edema, myalgia, paresthesia; glucose intolerance in some patients, so the label advises monitoring glucose and IGF-1. | No safety signal versus placebo over 7 days in the ileus trial; FDA cited immunogenicity risk from aggregation and impurities; long term effects untested. |
| Typical cost [8] [10] [12] [13] [15] | Egrifta WR has no published list price; one retail cash listing put a 28 day kit at about 10,709 USD (checked 2026-09-22). Compounded tesamorelin has no lawful price because tesamorelin is a biologic; dated prices are on the tesamorelin cost page. | Not available through licensed channels; research chemical products sold for human use are unapproved drugs. |
| Note: Prices at the verification date change often. | ||
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Tesamorelin | Ipamorelin |
|---|---|---|
| Class | Synthetic 44 amino acid analog of human growth hormone releasing hormone with an N-terminal trans-3-hexenoic acid modification that resists enzymatic degradation | Synthetic pentapeptide growth hormone secretagogue; selective agonist at the ghrelin receptor (GHS-R1a) |
| What it is | FDA approved lab-made growth hormone releasing hormone (Egrifta, 2010) that cuts deep belly fat about 15% in HIV lipodystrophy and cut liver fat in a trial. | Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; its one randomized placebo controlled trial, after bowel surgery, found no benefit. |
| Evidence | Evidence: Human RCT evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: FDA approved | Regulatory: Nomination withdrawn |
| Compounding | FDA approved as Egrifta (tesamorelin for injection) on November 10, 2010, for reduction of excess abdominal fat in HIV infected adults with lipodystrophy; Egrifta SV, a 2 mg vial formulation, was approved in 2019, and Egrifta WR, an 11.6 mg vial formulation, in March 2025. Tesamorelin is a 44 amino acid protein, and on March 23, 2020 FDA deemed the Egrifta application (022505) to be a biologics license. FDA states that biological products are not eligible for the 503A or 503B compounding exemptions, so compounded tesamorelin sold by telehealth and anti-aging clinics has no lawful basis, and Egrifta WR by prescription is the only lawful product. A clinician may prescribe Egrifta WR off-label, but use for fat loss in people without HIV has only limited trial support. | Not FDA approved for any use. Ipamorelin was nominated for the 503A bulks list and placed in Category 2. FDA cited immunogenicity risk from aggregation or peptide related impurities, unnatural amino acids that complicate characterization, and a published report of serious adverse events, including a death, when it was given intravenously. On October 29, 2024 the Pharmacy Compounding Advisory Committee voted against adding ipamorelin free base or ipamorelin acetate to the 503A bulks list. FDA now lists ipamorelin acetate among 503A nominations withdrawn by the nominators, which puts it in no 503A category and outside FDA's interim policy. Ipamorelin acetate also remains in 503B Category 2, added September 29, 2023. It is not on the 503A bulks list, so as of the last verification date neither 503A pharmacies nor 503B outsourcing facilities have a federal basis to compound it. |
| WADA | WADA: WADA prohibited | WADA: WADA prohibited |
| Routes | Subcutaneous injection into the abdomen once daily (Egrifta WR, Egrifta SV), No oral, sublingual, or nasal form is FDA approved or tested in a published trial | Subcutaneous injection (as sold, no human pharmacokinetic publication), Intravenous infusion (human ileus trial), Intranasal (anti-doping metabolite study only) |
| Typical cost | Egrifta WR has no published list price; a retail cash listing put one 28 day kit at about 10,709 USD, and a manufacturer co-pay program helps eligible commercially insured patients with the approved HIV indication. Compounded tesamorelin has no lawful price: tesamorelin is a biologic, and FDA states biological products are not eligible for the 503A or 503B compounding exemptions. Prices checked 2026-09-22. | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Last verified |
Has tesamorelin been tested directly against ipamorelin?
No published trial has compared tesamorelin and ipamorelin directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do tesamorelin and ipamorelin cost?
| Dimension | Tesamorelin | Ipamorelin |
|---|---|---|
| Typical cost | $10,709 per month | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Price detail | Egrifta WR (tesamorelin) cost | Ipamorelin price by channel |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Ipamorelin page.
Are tesamorelin and ipamorelin combined?
Tesamorelin and ipamorelin are sold together in the premixed blend below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend page covers what is in each product, the evidence for each ingredient, and legal status.
- Tesamorelin and ipamorelin: No federal basis to compound.
Frequently asked questions
Which is better for reducing belly fat?
Tesamorelin is the only one with trial evidence: it reduced visceral fat by 15.4% relative to placebo over 26 weeks in people with HIV. Ipamorelin has never been tested for body composition in humans. [1] [3]
Do they work the same way?
No. Tesamorelin mimics growth hormone releasing hormone at the GHRH receptor, while ipamorelin mimics ghrelin at the growth hormone secretagogue receptor. Both end in pituitary GH release through different signals. [4] [6]
Can I get either one legally?
Tesamorelin yes, but only as Egrifta WR or Egrifta SV by prescription; it became a biologic in 2020, and biologics cannot be compounded under 503A. Ipamorelin has no federal basis to be compounded after its Category 2 listing and withdrawn 503A nomination. [6] [7] [8] [10] [13]
Does tesamorelin raise blood sugar?
In the pooled phase 3 trials glucose parameters did not differ meaningfully from placebo, and the liver fat trial found no difference in glucose or HbA1c, but the label notes glucose intolerance in some patients and advises monitoring. [1] [2] [6]
Are they allowed in sport?
No. Both are prohibited at all times under WADA section S2. [9]
Conditions studied
From the blog
- Ipamorelin side effects and benefits: what studies show
Ipamorelin side effects in its one human trial matched placebo, but FDA flags serious events with IV use. Claimed benefits for muscle, fat loss, and sleep are untested. Not FDA approved.
- Tesamorelin side effects: what the FDA label and trials show
Tesamorelin side effects from the Egrifta label and phase 3 trials: injection site reactions, joint pain, swelling, glucose and IGF-1 effects, allergic reactions, and who should not use it.
- Tesamorelin vs sermorelin vs ipamorelin: evidence and legality
Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010PubMed 20554713, 2010
- [2]Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019PubMed 31611038, 2019
- [3]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
- [4]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
- [5]Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther 2009PubMed 19289567, 2009
- [6]FDA prescribing information for Egrifta formulations (tesamorelin for injection), via DailyMedFDA
- [7]FDA: Compounding and the FDA, questions and answersFDA
- [8]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists, and withdrawn nominations)FDA
- [9]WADA Prohibited List, section S2 (GHRH analogues and growth hormone secretagogues)WADA
- [10]FDA prescribing information for Egrifta WR (tesamorelin) for injection, 11.6 mg vial, via DailyMed (Indications, Dosage and Administration, Warnings and Precautions, Use in Specific Populations, and Clinical Studies sections)FDA, 2025
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 30). Tesamorelin vs ipamorelin: evidence, cost, and legality. https://peptideagent.ai/compare/tesamorelin-vs-ipamorelin- HTML link
<a href="https://peptideagent.ai/compare/tesamorelin-vs-ipamorelin">Tesamorelin vs ipamorelin: evidence, cost, and legality</a>, PeptideAgent, updated September 30, 2026.